Cutting Edge: ROR1/CD19 Receptor Complex Promotes Growth of Mantle Cell Lymphoma Cells Independently of the B Cell Receptor–BTK Signaling Pathway

Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas

(2018) Malik Bisserier et al.   BLOOD

Wnt5a induces ROR1 to recruit DOCK2 to activate Rac1/2 in chronic lymphocytic leukemia

(2018) Md Kamrul Hasan et al.   BLOOD

Signalling for B cell survival

(2018) Edina Schweighoffer et al.   CURRENT OPINION IN CELL BIOLOGY

Cirmtuzumab inhibits ibrutinib-resistant, Wnt5a-induced Rac1 activation and proliferation in mantle cell lymphoma

(2018) Jian Yu et al.   Oncotarget

Wnt5a causes ROR1 to complex and activate cortactin to enhance migration of chronic lymphocytic leukemia cells

(2018) Md Kamrul Hasan et al.   LEUKEMIA

Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas

(2017) Stephen J. Schuster et al.   NEW ENGLAND JOURNAL OF MEDICINE

Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma

(2017) Xiaohong Zhao et al.   Nature Communications

Mantle Cell Lymphoma

(2016) Chan Yoon Cheah et al.   JOURNAL OF CLINICAL ONCOLOGY

Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents

(2016) Arati A. Inamdar et al.   Oncotarget

Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results

(2015) M. L. Wang et al.   BLOOD

Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1

(2015) Michael Y. Choi et al.   Clinical Lymphoma Myeloma & Leukemia

Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation

(2015) Jian Yu et al.   JOURNAL OF CLINICAL INVESTIGATION

Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells

(2014) Jiao Ma et al.   BRITISH JOURNAL OF HAEMATOLOGY

Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib

(2014) Jennifer A. Woyach et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ovarian cancer stem cells express ROR1, which can be targeted for anti–cancer-stem-cell therapy

(2014) Suping Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S BTK Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma

(2014) D. Chiron et al.   Cancer Discovery

Targeting pathological B cell receptor signalling in lymphoid malignancies

(2013) Ryan M. Young et al.   NATURE REVIEWS DRUG DISCOVERY

Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

(2013) Michael L. Wang et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

(2013) John C. Byrd et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Onco-Embryonic Antigen ROR1 Is Expressed by a Variety of Human Cancers

(2012) Suping Zhang et al.   AMERICAN JOURNAL OF PATHOLOGY

CD19 is a major B cell receptor–independent activator of MYC-driven B-lymphomagenesis

(2012) Elaine Y. Chung et al.   JOURNAL OF CLINICAL INVESTIGATION

Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia

(2011) David L. Porter et al.   NEW ENGLAND JOURNAL OF MEDICINE